Voya Investment Management LLC Purchases 19,381 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Voya Investment Management LLC lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 40.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 67,277 shares of the company's stock after purchasing an additional 19,381 shares during the quarter. Voya Investment Management LLC owned about 0.07% of ARS Pharmaceuticals worth $710,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in shares of ARS Pharmaceuticals during the 4th quarter valued at approximately $73,000. Compass Capital Corp MA ADV bought a new stake in ARS Pharmaceuticals in the fourth quarter valued at $106,000. Teacher Retirement System of Texas acquired a new position in shares of ARS Pharmaceuticals during the fourth quarter valued at $122,000. Amica Mutual Insurance Co. acquired a new position in shares of ARS Pharmaceuticals during the fourth quarter valued at $151,000. Finally, PEAK6 LLC acquired a new position in ARS Pharmaceuticals during the fourth quarter worth about $162,000. Institutional investors and hedge funds own 68.16% of the company's stock.

Insider Buying and Selling

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction on Monday, April 7th. The stock was sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the transaction, the director now directly owns 210,346 shares of the company's stock, valued at $2,587,255.80. The trade was a 19.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now directly owns 7,696 shares of the company's stock, valued at $107,744. This represents a 56.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,602 shares of company stock worth $1,311,041. 40.10% of the stock is owned by corporate insiders.

ARS Pharmaceuticals Trading Down 9.2%

Shares of SPRY traded down $1.23 during trading hours on Wednesday, hitting $12.13. 1,496,343 shares of the stock traded hands, compared to its average volume of 1,205,199. ARS Pharmaceuticals, Inc. has a 1-year low of $7.55 and a 1-year high of $18.51. The firm has a market capitalization of $1.19 billion, a PE ratio of -23.77 and a beta of 0.84. The business has a fifty day moving average of $13.25 and a 200-day moving average of $12.92.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The company had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million. As a group, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SPRY shares. Oppenheimer started coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an "outperform" rating and a $40.00 price target on the stock. Scotiabank began coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 target price for the company. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Raymond James upped their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a research note on Tuesday, January 14th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ARS Pharmaceuticals has a consensus rating of "Buy" and an average target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.